The effect of ethyldeshydroxy-sparsomycin and cisplatin on the intracellular glutathione level and glutathione S-transferase activity

Anti-Cancer Drugs

Volumn 8, Issue 4, 1997, Pages 349-357

  Hofs, Henny P ^a,d   Wagener, Theo D J ^a   De Valk Bakker, Veronique ^a   Van Rennes, Helga ^a   Doesburg, Wim H ^b   Ottenheijm, Harry C J ^b,c   De Grip, Wim J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^c NV ORGANON   (Netherlands)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Cisplatin; Drug resistance; Glutathione; Glutathione S transferase,; Sparsomycin

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; ETHYLDEHYDROXYSPARSOMYCIN; GLUTATHIONE; GLUTATHIONE TRANSFERASE; SPARSOMYCIN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG RESISTANCE; LEUKEMIA CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0030975896     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199704000-00007     Document Type: Article

References (41)

1. Broek van den LAGM, Lazaro E, Zylicz Z, et al. Lipophilic analogues of sparsomycin as strong inhibitors of protein synthesis and tumor growth: a structure-activity relationship study. J Med Chem 1989; 32: 2002-15.
2. Zylicz Z, Wagener DJTh, Rennes H van, et al. In vivo antitumor activity of sparsomycin and its analogues in eight murine tumour models. Invest New drugs 1988; 6: 285-92.
3. Hofs HP, Wagener DJTh, De Valk-Bakker V, et al. Potentiation of cisplatin antitumor activity by ethyldeshydroxy-sparsomycin in L1210 leukaemia. Anticancer Res 1992; 12: 167-70.
4. Hofs HP, Wagener DJTh, De Valk-Bakker V, et al. Correlation of the in vitro cytotoxicity of ethyldeshydroxy-sparsomycin and cisplatin with the in vivo antitumor activity in murine leukaemia and two resistant L1210 subclones. Cancer Chemother Pharmacol 1993; 31: 289-94.
5. Hromas RA, Andrews PA, Murphy MP, Burns CP. Glutathione depletion reverses cisplatin resistance in murine L1210 leukemia cells. Cancer Lett 1987; 34: 9-13.
6. Meijer C, Mulder NH, Hospers GAP, Uges DRA, de Vries EGE. The role of glutathione in resistance to cisplatin in a human small cell lung cancer cell line. Br J Cancer 1990; 62: 72-7.
7. Ozols RF, Hamilton TC, Young RC. Cellular glutathione levels and sensitivity to radiation and antineoplastic agents in human ovarian cancer. Prog Clin Biol Res 1988; 276: 287-93.
8. Russo A, DeGraff W, Friedman N, Mitchell JB. Selective modulation of glutathione levels in human normal versus tumor cells and subsequent differential response to chemotherapy drugs. Cancer Res 1986; 46: 2845-8.
9. Kraker AJ, Moore CW. Accumulation of cis-diamminedichloroplatinum(II) and platinum analogues by platinum-resistant murine leukemia cells in vitro. Cancer Res 1988; 48: 9-13.
10. Richon VM, Schulte N, Eastman A. Multiple mechanisms of resistance to cis-diamminedichloroplatinum(II) in murine leukemia L1210 cells. Cancer Res 1987; 47: 2056-61.
11. Sekiya S, Oosaki T, Andoh S, Suzuk N, Akaboshi M, Takamizawa H. Mechanisms of resistance to cis-diamminedichloroplatinum(II) in a rat ovarian carcinoma cell line. Eur J Cancer Clin Oncol 1989; 25: 429-37.
12. Fram RJ, Woda BA, Wilson JM, Robichaud N. Characterization of acquired resistance to cis-diamminedichloroplatinum(II) in BE human colon carcinoma cells. Cancer Res 1990; 50: 72-7.
13. Hospers GAP, Mulder NH, De Vries EGE. Mechanisms of cellular resistance to cisplatin. Med Oncol Tumor Pharmacother 1988; 5: 145-51.
14. Puchalski RB and Fahl WE. Expression of recombinant glutathione S-transferase π, Ya, or Yb1 confers resistance to alkylating agents. Proc Natl Acad Sci USA 1990; 87: 2443-7.
15. Saburi Y, Nakagawa M, Ono M, et al. Increased expression of glutathione S-transferase gene in cis-diamminedichloroplatinum(II)-resistant variants of a chinese hamster ovary cell line. Cancer Res 1989; 49: 7020-5.
16. Andrews PA, Murphy, MP, Howell SB. Differential sensitization of human ovarian carcinoma and mouse L1210 cells to cisplatin and melphalan by glutathione depletion. Mol Pharmacol 1986; 30: 643-50.
17. Andrews PA, Schiefer MA, Murphy MP, Howell SB. Enhanced potentiation of cisplatin cytotoxicity in human ovarian carcinoma cells by prolonged glutathione depletion. Chem-Biol Interac 1988; 65: 51-8.
18. Bier H. Erhöhung der chemosensitivität gegenüber cisplatin durch glutathione-depletion mit buthionin sufoximin. Laryngo-Rhino-Otol 1990; 69: 16-20.
19. Andrews PA, Velury S, Mann SC, Howell SB. Cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res 1988; 48: 68-73.
20. Lee FYF, Vessey A, Rofstad E, Siemann DW, Sutherland RM. Heterogeneity of glutathione content in human ovarian cancer. Cancer Res 1989; 49: 5244-8.
21. Hamada H, Okochi E, Watanabe M, et al. Mr 85,000 membrane protein specifically expressed in adriamycin-resistant human tumor cells. Cancer Res 1988; 48: 7082-7.
22. Udenfriend S, Stein S, Bohlen P, et al. Fluorescamine: a reagent for assay of amino acids, peptides, proteins, and primary amines in the picomole range. Science 1972; 178: 871-2.
23. Lai CY. Detection of peptides by fluorescence methods. Methods Enzymol 1977; 47: 236-43.
24. Tietze F. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem 1969; 27: 502-22.
25. Hissin PJ, Hilf R. A fluorometric method for determination of oxidized and reduced glutathione in tissues. Anal Biochem 1976; 74: 214-26.
26. Habig WH, Pabst MJ, Jakoby WJ. Glutathione S-transferases: the first enzymatic step in mercapturic acid formation. J Biol Chem 1974; 249: 7130-9.
27. Mannervik B. The isoenzymes of glutathione transferase. Adv Enzymol Relat Areas Mol Biol 1985; 57: 357-417.
28. Mannervik B, Danielson UH. Glutathione transferases - structure and catalytic activity. CRC Crit Rev Biochem 1988; 23: 283-337.
29. Mannervik B, Awasthi YC, Board PG, et al. Nomenclature for human glutathione transferases. Biochem J 1992; 282: 305-8.
30. Radel S, Fredericks W, Mayhew E, Baker R. P-glycoprotein expression and modulation of cell-membrane morphology in adriamycin-resistant P388 leukemia cells. Cancer Chemother Pharmacol 1990; 25: 241-6.
31. Dorr TC, Liddil JD, Trent JM, Dalton WS. Mitomycin C resistant L1210 leukemia cells: association with pleiotropic resistance. Biochem Pharmacol 1987; 36: 3115-20.
32. Hershko A, Ciechanover A. Mechanisms of intracellular protein breakdown. Annu Rev Biochem 1982; 51: 335-64.
33. Schimke RT. On the roles of synthesis and degradation in regulation of enzyme levels in mammalian tissues. Curr Topics Cell Regul 1969; 1: 77-124.
34. Meister A, Anderson ME. Glutathione. Annu Rev Biochem 1983; 52: 711-60.
35. Cordon BJ. Reaction of Platinum(II) antitumor agents with sulfhydral compounds and the implications for nephrotoxicity. Inorg Chim Acta 1987; 137: 125-30.
36. Reishus JW, Martin DS Jr. Cis-dichlorodiammineplatinum(II): acid hydrolyses and isotopic exchange of the chloride ligands. J Am Chem Soc 1961; 83: 2457-67.
37. Cleare MJ, Hydes PC, Malerbe BW, Watkins DM. Antitumor platinum complexes: relationships between chemical properties and activity. Biochimie 1978; 60: 835-50.
38. Andrews PA, Murphy MP, Howell SB. Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol 1987; 19: 149-54.
39. Kelley SL, Basu A, Teicher BA, et al. Overexpression of metallothionein confers resistance to anticancer drugs. Science 1988; 241: 1813-5.
40. Schilder RJ, Hall L, Monks A, et al. Metallothionein gene expression and resistance to cisplatin in human ovarian cancer. Int J Cancer 1990; 45: 416-22.
41. Farnworth P, Hillcoat B, Roos IA. Metallothionein-like proteins and cell resistance to cis-dichlorodiammineplatinum(II) in L1210 cells. Cancer Chemother Pharmacol 1990; 25: 411-7.